| Piedmont Lithium (NASDAQ: PLL) Chemical Plant PFS Demonstrates Exceptional Economics of USA Location |
| |
|
Piedmont Lithium (NASDAQ: PLL) reported the results of the Company’s pre-feasibility study (PFS) for its proposed lithium hydroxide chemical plant in Kings Mountain, North Carolina, USA. The PFS assumes a stand-alone merchant Chemical Plant that would convert spodumene concentrate purchased on the global market to battery-grade lithium hydroxide. Concurrently, Piedmont has updated the scoping study for its integrated mine-to-hydroxide project to reflect the updated Chemical Plant PFS. Both studies confirm that Piedmont will be a strategic and low-cost producer of battery-grade lithium hydroxide.
Why It Matters: Piedmont benefits from access to the exceptional infrastructure, low operating costs and low corporate taxes enjoyed by American industrial companies. Piedmont’s Chemical Plant would create an alternative to the numerous merchant spodumene converters currently operating in China and dominating the world lithium hydroxide market, thus providing US and European automotive companies a secure and independent American source of the lithium hydroxide required for their supply chains.
Key Quote: “The Chemical Plant PFS demonstrates the economic benefit of developing a lithium chemical business in North Carolina, USA, with its exceptional infrastructure, low operating costs and competitive tax regime.” – Keith Phillips, President
The Backstory: Location is one of the standout features of the Piedmont project, with access to excellent infrastructure and transport options, close proximity to existing lithium chemical processing facilities operated by Livent (NYSE: LTHM) and Albemarle (NYSE: ALB), and within reach of 13 auto manufacturing facilities. Compared to Australian- and Canadian-based projects, North Carolina offers a significantly lower-cost operating environment (labor, power/gas/diesel, transport), which is further boosted by the absence of government royalties and a low tax rate environment. Lithium is on the US Government’s Critical Minerals list, giving the project significant strategic value as being the only conventional US lithium development project.
Disclosure
Piedmont Lithium (PLL) is a client of RedChip Companies, Inc. PLL agreed to pay RedChip Companies, Inc. a quarterly cash fee of $20,000, beginning in April 2019, for 12 months of RedChip investor awareness services.
|
|
| |
|
| Esports Entertainment Group (NASDAQ: GMBL) Forms New Jersey Subsidiary to Pursue Licensing Strategy in US |
| |
|
Esports Entertainment Group (NASDAQ: GMBL), a licensed online gambling company with a focus on esports wagering and 18+ gaming, announced the formation of a new wholly owned subsidiary, “GMBL New Jersey Inc.”, for the express purpose of commencing its strategy to pursue gambling licenses throughout the United States that will further the Company’s esports gambling market.
Why it Matters: The Company expects to make its first such application with the State of New Jersey in the near future and will provide updates for each anticipated application as they are submitted in each available jurisdiction. The Company’s US operations will be based in New Jersey, where the Company expects to establish facilities and operating personnel.
Key Quote: “The US market represents a very big opportunity for us and thanks to the continued support of our valued shareholders, we intend to aggressively pursue it in 2020 and beyond.” - Grant Johnson, CEO
The Backstory: Esports Entertainment Group is a licensed online gambling company with a specific focus on esports wagering and 18+ gaming. Esports Entertainment offers fantasy, pools, fixed odds and exchange style wagering on esports events in a licensed, regulated and secure platform to the global esports audience at vie.gg. In addition, Esports Entertainment intends to offer users from around the world the ability to participate in multi-player mobile and PC video game tournaments for cash prizes. Esports Entertainment is led by a team of industry professionals and technical experts from the online gambling and the video game industries, and esports. The Company holds a license to conduct online gambling and 18+ gaming on a global basis in Curacao, Kingdom of the Netherlands.
Disclosure
Esports Entertainment Group, Inc. (GMBL) is a client of RedChip Companies, Inc. GMBL agreed to pay RedChip Companies, Inc. a $4,000 monthly cash fee, beginning in June 2018, and 225,000 shares of Rule 144 stock for RedChip investor awareness services.
|
|
| |
|
| Genetic Technologies (NASDAQ: GENE) Announces Pricing of $8.0 Million Public Offering |
| |
|
Genetic Technologies Limited (NASDAQ: GENE), a leader in the development of genetic risk assessment tests, today announced that it has priced a public offering of 4,000,000 American Depositary Shares, each representing six hundred (600) of the Company’s ordinary shares, at an effective purchase price of $2.00 per ADS. The closing of the offering is expected to occur on or about May 28, 2020, subject to the satisfaction of customary closing conditions.
Why It Matters: The gross proceeds from this offering are expected to be $8.0 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering to support the introduction and distribution of our new products in the United States, for general product research and development, including the development of polygenic risk tests, and reimbursement studies with TGen in the United States, for implementation of our consumer initiated testing platform, preparation for potential COVID-19 testing and COVID-19 risk test for developing serious disease from contracting COVID-19 and for working capital and new equipment purchases.
The Backstory: Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products GeneType for Breast Cancer for non-hereditary breast cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class. Genetic Technologies has capacity for COVID-19 testing and is developing a pipeline of risk assessment products including a COVID-19 risk test for the risk of developing serious disease if a person were to contract COVID-19.
Disclosure
Genetic Technologies (GENE) is a client of RedChip Companies, Inc. GENE agreed to pay RedChip Companies, Inc. a $7,500 monthly cash fee, beginning in March 2019, for six (6) months of RedChip investor awareness services.
|
|
| |
|
| Can-Fite BioPharma (NYSE American: CANF) Receives Notice of Allowance for Namodenoson Patent in the Treatment of NASH & NAFLD from U.S. Patent and Trademark Office |
| |
|
Can-Fite BioPharma (NYSE American: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced the U.S. Patent and Trademark Office (PTO) has issued a Notice of Allowance for the Company’s patent titled, "Method for treating NASH accompanied by fibrosis using CI-IB-MECA". The allowance follows Can-Fite’s recent announcement of highly encouraging data from its Phase II study of its drug candidate Namodenoson, generically known as CI-IB-MECA, in the treatment of non-alcoholic fatty liver disease (NAFLD) with or without non-alcoholic steatohepatitis (NASH).
Why It Matters: The allowed patent covers the use of the A3 adenosine receptor (A3AR) in reducing ectopic fat accumulation, particularly in fatty liver. The patent specifically addresses preparation of a pharmaceutical composition for reducing fat accumulation and a method of treating conditions associated with fat accumulation such as fatty liver diseases including NASH and NAFLD.
Key Quote: “We are very pleased to receive this Notice of Allowance from the U.S. PTO at this time, immediately following an analysis of Phase II data that show Namodenoson is highly effective in treating and reversing fatty liver. At the optimal 25 mg dosage, Namodenoson eliminated NASH in the Phase II patient population. The protection provided by the allowed patent has a high value for us, as we move forward into advanced stage clinical trials in this indication, and as we evaluate distribution partnerships for Namodenoson.” – Dr. Pnina Fishman, CEO
The Backstory: Can-Fite is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion-dollar markets in the treatment of cancer, inflammatory disease and COVID-19. The Company's lead drug candidate, Piclidenoson, is currently in Phase III trials for rheumatoid arthritis and psoriasis. Piclidenoson has been approved for a pilot clinical trial in Israel to treat COVID-19 infected patients with moderate-to-severe symptoms. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and successfully achieved its primary endpoint in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,500 patients in clinical studies to date.
Disclosure
Can-Fite Biopharma (CANF) is a client of RedChip Companies, Inc. CANF agreed to pay RedChip Companies, Inc. a cash fee of $5,000 monthly, beginning in August 2019, and 16,500 shares of CANF Rule 144 stock for 6 months of RedChip investor awareness services and consulting services.
|
|
| |
|
| Cuentas (OTCQB: CUEN) Files Application for Uplisting to NASDAQ |
| |
|
Cuentas (OTCQB: CUEN), a leading FinTech provider of mobile banking and payment solutions aimed at serving Hispanic and Latino communities, submitted its formal application to list its common shares on the NASDAQ Capital Market.
Key Quote: “Becoming a NASDAQ-listed company will be a significant milestone for Cuentas that builds on our momentum from the recent launch of our Cuentas GPR card and Mobile App.” – Michael De Prado, President
The Backstory: The Cuentas Mobile App and prepaid Mastercard services provide a comprehensive financial solution for the 20 million+ underbanked or unbanked U.S. Hispanic & Latino community, providing access to the U.S. financial system to those who cannot or prefer not to bank at a traditional financial institution while enabling greater functionality than a traditional bank offers. A proprietary general-purpose reloadable (GPR) card, the Cuentas prepaid Mastercard provides an FDIC insured account with banking features, ATM access, direct deposit, cash reload, free Cuentas App to Cuentas App "send" or "request" money transfers , and mobile banking capabilities, among other key Cuentas App features - such as purchasing discounted gift cards, including Amazon Cash, Sony Playstation, Microsoft Xbox, Burger King, etc. and the ability to scan & load Mass Transit Cards (available in Los Angeles, Connecticut, Michigan, and expected shortly, New York City). Upcoming App upgrades will also include international cross border remittances and other services such as international Bill Pay whereas US Cuentas App account holders using the Cuentas Mobile App will be able to directly pay utility and other bills for relatives in other countries such as Mexico.
Disclosure
Cuentas (CUEN) is a client of RedChip Companies, Inc. CUEN agreed to pay RedChip Companies, Inc., a $4,000 monthly cash fee, beginning in April 2020, for the first three months, $8,000 per month for month four through six for RedChip investor awareness services. CUEN will pay RC 5,000 shares of Rule 144 Stock when the stock price reaches $5.00, and another 5,000 shares of Rule 144 Stock when the stock price reaches $8.00.
|
|
| |
|
| Nemaura Medical (NASDAQ: NMRD) 2020 Stock Incentive Plan Approved at Annual General Meeting |
| |
|
Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor ("CGM"), together with BEAT®diabetes, a planned health subscription service designed to help people with Type 2 diabetes and prediabetes through personalized lifestyle coaching, announced its 2020 Omnibus Incentive Plan ("Plan") was approved by shareholder vote at the Company’s Annual General Meeting on May 15, 2020. A maximum of 1,000,000 shares of Common Stock have been made available for Awards under the Plan.
Key Quote: “We want to thank our shareholders for approving our stock incentive plan which improves our ability to retain top staff and attract new senior level management as we move into the revenue growth phase of our operations. Based on positive data from an early head-to-head comparison with a major incumbent CGM, we believe sugarBEAT® is well positioned to disrupt the current status quo. As we execute on the global commercialization strategy of this innovative technology, having the right team in place will be critical to our success.” – Dr. Faz Chowdhury, CEO
The Backstory: Nemaura Medical is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT™, and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse and prevent the onset of diabetes. Nemaura is planning to submit a PMA application for sugarBEAT® during the second quarter of 2020 for FDA review of this device under medical device regulations. proBEAT™ comprises a non-invasive glucose monitor and a digital healthcare subscription service and is due to be launched in the US as a general wellness product.
Disclosure
Nemaura Medical (NMRD) is a client of RedChip Companies. NMRD agreed to pay RedChip a monthly cash fee of $6,000 and 15,000 shares of Rule 144 stock for three months of investor awareness services.
|
|
| |
|
| SinglePoint (OTCQB: SING) Reports 300% Increase in Q1 Revenue Driven by Solar Growth |
| |
|
SinglePoint (OTCQB: SING) reported first quarter total sales of $1,075,222, a 300% growth compared to the same period in 2019. The majority of the revenue was attributable to the acquisition of Direct Solar America and the backlog of projects developed throughout Q4.
Why It Matters: Direct Solar America had amassed a record pipeline of (solar bookings) throughout Q4 of 2019 and the early period of Q1 2020 many of which installed during Q1 2020. During the first quarter, Direct Solar America added multiple new markets, now totaling 30 states. The company saw record bookings during February closing over 40 residential sales. Due to the challenges presented by the operational disruptions businesses and consumers faced in response to the COVID-19 virus March was slower than anticipated. The Company accelerated the transition to a completely digital sales platform facilitating contactless solar sales, which enabled Direct Solar America to quickly expand into new markets. The digital sales platform has reduced costs as highlighted and featured in GreenTech Media, an industry leader focused on the clean energy industry, discussing the changes made and how they will impact the company in the near and long term.
Key Quote: “Direct Solar America and our consumer product 1606 Original Hemp are both gaining traction and revenue growth. We continue to analyze and to take actions to transform and realign our business opportunities and we remain bullish on the long-term ability for the company to grow revenues, improve the balance sheet and increase shareholder value.” – Greg Lambrecht, Chairman & CEO
The Backstory: Founded in 2011, SinglePoint invests in and acquires brands and companies that will benefit from injection of growth capital and the sales and marketing expertise of SinglePoint. The company portfolio currently includes solar, hemp, and technology applications. SinglePoint is working to grow the company to a multinational brand.
Disclosure
SinglePoint, Inc. (SING) is a client of RedChip Companies, Inc. SING agreed to pay RedChip Companies, Inc. a $10,000 monthly cash fee, beginning in June 2019, for RedChip investor awareness services and consulting services.
|
|
| |
|
| |
| Quote of the Week |
| |
"You got to make a decision to devote a decade of your life, it takes ten years of your life to accomplish anything."
- Manny Villafana, CEO Kips Bay Medical |
|
|
|
|
|
|
|
| About RedChip |
| |
| RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. |
| |
| RedChip Disclosure |
| |
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and view RedChip’s Disclosures. |
|
| |
|
|
| |
|
|
Copyright © 2020 RedChip Companies, Inc. All Rights Reserved.
You are receiving this message because this email address has signed up to receive News Alerts.
|
|
|
|
|
